3Israel E,Chinchilli VM,Ford JG,et al.Use of regularly scheduled albuterol treatment in asthma:genotype-stratified,randomised,placebo-controlled cross-over trial[J].Lancet,2004,364(9444):1505-1512.
4Bleecker ER,Postma DS,Lawrance RM,et al.Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy:a pharmacogenetic analysis of two randomised studies[J].Lancet,2007,370(9605):2118-2125.
5Bleecker ER,Nelson HS,Kraft M,et al.Beta2-receptor polymor-phisms in patients receiving salmeterol with or without fluticasone propionate[J].Am J Respir Crit Care Med,2010,181(7):676-687.
6Bisgaard H,Szefler S.Long-acting beta2 agonists and paediatric asthma[J].Lancet,2006,367(9507):286-288.
7Currie GP,Lipworth BJ.Bronchoprotective effects of leukotriene receptor antagonists in asthma:a meta-analysis[J].Chest,2002,122(1):146-150.
8Dal Negro RW,Borderias L,Zhang Q et al.Rates of asthma attacks in patients with previously inadeQately controlled mild asthma treated in clinical practice with combination drug therapy:an exploratory post-hoc analysis[J].BMC Pulm Med,2009,9:10.
9Bjermer L,Bisgaard H,BousQet J,et al.Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults:one year,double blind,randomised,comparative trial[J].BMJ,2003,327(7420):891.
10Ducharme FM,Lasserson TJ,Cates CJ.Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma[DB/OL].Cochrane Database Syst Rev,2006,18(4):CD003137.
